Document is current
Any future updates will be listed below
-
Authors
Lim, Su Yin
da Silva, Ines Pires
Adegoke, Nurudeen A.
Lo, Serigne N.
Menzies, Alexander M.
Carlino, Matteo S.
Scolyer, Richard A.
Long, Georgina V.
Lee, Jenny H.
Rizos, Helen
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council (2012860, 2012860)
- License Information
-
More Information
Article History
Received: 13 August 2024
Accepted: 4 October 2024
First Online: 11 October 2024
Declarations
:
: Written consent was obtained from all patients included in this study (Human Research ethics approval from Royal Prince Alfred Hospital - Protocol X15-0454 & HREC/11/RPAH/444).
: Not applicable.
: IPdS is on the advisory board of Merck Sharp & Dohme; has received fees for professional services from Roche, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, and Pierre Fabre; and has had travel support from Bristol Myers Squibb and Merck Sharp & Dohme. MC has served on advisory boards or as a consultant for Amgen, BMS, Eisai, Ideaya, Merck, Sharp & Dohme (MSD), Nektar, Novartis, Oncosec, Pierre-Fabre, Qbiotics, Regeneron, Roche, Merck, Moderna and Sanofi and received honoraria from BMS, MSD and Novartis. AMM is a consultant advisor for Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Roche, Pierre-Fabre and QBiotics. SNL has received fees for professional services from SkylineDx and a stipend for editorial services at the British Journal of Dermatology. JHL has received honorarium from Merck, Sharp & Dohme, Bristol-Myers Squibb, Sanofi, Novartis, AstraZeneca, Roche. JHL has received conference support from Novartis and Merck, Sharp & Dohme. RAS has received fees for professional services from MetaOptima Technology Inc., F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, GlaxoSmithKline. GVL is consultant advisor for Agenus, Amgen, Array Biopharma, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Evaxion, Hexal AG (Sandoz Company), Highlight Therapeutics S.L., Immunocore, Innovent Biologics USA, Merck Sharpe & Dohme, Novartis, PHMR Ltd, Pierre Fabre, Provectus, Qbiotics, Regeneron. All other authors declare no conflicts of interest.
